摘要
目的 探讨普伐他汀对急性冠状动脉综合症患者内皮功能的影响。方法 急性心肌梗死和不稳定心绞痛合并血胆固醇(TC)水平≥5.2mmol/L或低密度脂蛋白胆固醇(LDL)≥3.4mmol/L的患者,随机被分成安慰剂组(31例)和服用普伐他汀20mg/d(32例)的治疗组,观察12周。使用上臂肱动脉超声检测肱动脉内皮依赖流量介导性扩张(FMD)和内皮非依赖的对硝酸甘油的扩张反应。结果 入院及随机分组后TC和LDL水平在两组间相近。使用普伐他汀组,TC和LDL水平下降了23%(P<0.05)和33%(P<0.01)。FMD在安慰剂组变化不大,分别为5.41±0.73%(平均±SEM)和5.82±0.81%,但是普伐他汀组却明显升高,从4.90±0.81%升至6.90±0.79%,即为41%的相对增长。使用硝酸甘油后的血管扩张反应在两组相类似。结论 普伐他汀能有效降低血脂水平和改善血管内皮功能。
Objective Cholesterol lowering reduces coronary events. One mechanism could beimprovement of endothelial function. To investigate the effect Pravachol on endothelium-dependentvasodilation in acute coronary syndromes patients. Methods Patients with acute myocardial infractionor unstable angina and total cholesterol levels at admission≥5.2mmol∕L or LDL≥3.4mmol∕L wererandomized to placebo(n=31)or pravastatin 20mg daily (n=32)For 12 weeks. Branchial ultrasound was usedto measure endothelial-dependent flow-mediateddilatation(FMD) and response to endothelial-independentnitroglycerin.Result Total and LDL cholesterol levels were similar at admission and before random-ization in both groups. With pravastatin , but not with placebo, they decreased by 23%(P<0.05) and 33%(P<0.01) respectively. FMD was unchanged with placebo , 5.41±0.73%(mean±SEM) to 5.82±0.81%,butpravastatin,4.90±0.81% to 6.90±0.79%,representing a 41% relative increase.Responses to nitroglyc-erin were similar during the time course of the study in the 2 groups.Conclusions Cholesterolreduction with pravastatin initiated after Acute coronary syndrome improves endothelial function after12 weeks of therapy.
出处
《国际医药卫生导报》
2003年第22期10-12,共3页
International Medicine and Health Guidance News
